On May 26, Kelun-Biotech Biopharmaceutical rose 3.12% in regular trading, trading at 484.0 HKD/share, with trading volume of approximately 189 million HKD.

On the news front, the company has seen a series of R&D milestones driving momentum. Previously, the company announced that its core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) and RET inhibitor lunbotinib fumarate have both been selected for oral presentations at the metastatic non-small cell lung cancer session at the ASCO annual meeting. Notably, the Phase III OptiTROP-Lung05 study demonstrated that sac-TMT combined with pembrolizumab significantly extended progression-free survival versus pembrolizumab monotherapy in first-line PD-L1-positive advanced NSCLC, with an objective response rate of 70.2%. Additionally, the global Phase III TroFuse-005 study of sac-TMT in endometrial cancer successfully met both OS and PFS co-primary endpoints. China Post Securities also initiated coverage with a Buy rating, citing imminent global pipeline value realization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)